Business Wire

CA-AMBARELLA

21.6.2021 11:02:09 CEST | Business Wire | Press release

Share
Ambarella Expands Security AI Vision SoC Portfolio With Two New Families; Doubles Resolution to 32MP30 for 4K Multi-Imager Cameras With Advanced AI

Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/

“Security system designers desire higher resolutions, increasing channel counts, and ever faster and more ubiquitous AI capabilities,” explained John Lorenz, senior technology & market analyst, computing at Yole Développement (Yole). “Ambarella’s newest AI vision SoCs for security, the CV5S and CV52S, are competitive solutions for meeting the growing demands of the security IC sector, which we forecast to exceed $4 billion by 2025, with two-thirds of that being chips with AI capabilities.” (1)

The new CV5S SoC family supports multi-imager camera designs and can simultaneously process and encode four imager channels of up to 8MP, or 4K resolution, each at 30 frames per second (fps), while performing advanced AI on each 4K imager. These SoCs double the encoding resolution and memory bandwidth while consuming 30% less power than Ambarella’s prior generation.

The new CV52S SoC family targets single-sensor security cameras and supports 4K resolution at 60fps, while providing 4x the AI computer vision performance, 2x the CPU performance and 50% more memory bandwidth than its predecessors. This increase in neural network (NN) performance enables more AI processing to be performed at the edge, instead of in the cloud.

“The global security industry is rapidly moving to higher 4K resolutions while increasing AI algorithm capabilities, to achieve better recognition of people and objects, along with multiple imagers for a wider field of view and longer range,” said Jerome Gigot, senior director of marketing, Ambarella. “Our new CV5S and CV52S security AI vision SoC families respectively support 4K multi-imager or high-frame-rate 4K single-imager designs with high performance edge AI processing, allowing the development of cameras that do not need to compromise between image resolution and AI processing accuracy.”

In addition to security, there are many other AIoT applications that can take advantage of the high resolution and advanced AI processing provided by these new SoC families. For example, smart cities can leverage high edge AI performance and image resolution for improved traffic management, accident detection and automated speed control, as well as the rapid location of missing and stolen vehicles. Likewise, smart retail operations can use this resolution and advanced AI to better manage product placement, adjust cashier staffing for real-time line management, enhance warehouse product tracking, and provide more actionable intelligence at both the store and corporate levels.

Additional features of the new CV5S and CV52S families include:

  • Robust SDK created specifically for the security camera market
  • CVflow tools that are compatible across all security families
  • Dual Arm® A76 1.6GHz CPUs with 1MB of L3 memory; a 2x performance gain over the prior generation for faster customer applications
  • Enhanced ISP with excellent HDR, ISO low-light, dewarping and rotation performance
  • On-chip privacy masking to block out a portion of the captured scene
  • New PCIe and USB 3.2 interfaces, enabling more complex, multi-chip security system designs than prior generation
  • Strong on-chip cybersecurity hardware to ensure secure IP cameras, including secure boot, OTP and Arm TrustZone technology
  • Multiple video inputs, with support for up to 14 cameras using MIPI virtual channels
  • SLVS-EC interface on the CV5S for reduced system design complexity
  • Support for LPDDR4x, LPDDR5 and LPDDR5x DRAM

Availability

The CV5S and CV52S SoC families are expected to be available for sampling in October. For more information, contact Ambarella: https://www.ambarella.com/contact-us/ .

About Ambarella

Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving and robotics applications. Ambarella’s low-power systems on chip (SoCs) offer high-resolution video compression, advanced image processing and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com

All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications, and pricing at any time without notice. © 2021 Ambarella. All rights reserved.

1. Source: Cameras and computing for surveillance and security report , Yole Développement, 2020

Link:

ClickThru

Social Media:

https://www.facebook.com/ambarellacorp/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye